Gene expression profiling of Erlotinib sensitive and resistant human non small cell lung cancer (NSCLC) cell lines

We characterized the gene expression profile of Epithelial Growth Factor Receptor (EGFR) inhibitor (Erlotinib)-sensitive and resistant human NSCLC cell lines. Total RNA was extracted from the cell lines and expression profiles were studied by Agilent microarray analysis. Wide changes in gene expression profiles occur in the Erlotinib-resistant cell lines when compared with their parental cell lines (HCC827 and HCC4006). Erlotinib-resistant HCC827- (RA1, RA2, RB1, RB1.1, RB2) and HCC4006-derived NSCLC were compared to their parental sensitive cell lines. A total of 16 samples were analyzed, two replicates for each cell line. Citation for manuscript describing cell line establishment: Presutti D, Santini S, Cardinali B, Papoff G, Lalli C, Samperna S, Fustaino V, Giannini G, Ruberti G. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells. PLoS One. 2015 Nov 18;10(11):e0143333. doi: 10.1371/journal.pone.0143333. eCollection 2015.